PittsburghV1, Main, Exploration, bibRecord, 00A754

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Identifieur interne : 00A754 ( Main/Exploration ); précédent : 00A753; suivant : 00A755

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Auteurs : Ahmad A. Tarhini [États-Unis] ; John M. Kirkwood [États-Unis]

Source :

Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2009-12.

RBID : ISTEX:3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC

Descripteurs français

Wicri :
- topic : Adjuvant, Vaccin.

English descriptors

KwdEn :
- Adjuvant, Adjuvant interferon, Adjuvant therapy, Autoimmunity, Clin, Cutaneous, Cutaneous melanoma, Cytokine, Eggermont, Eortc, Individual patient data, Interferon, Intergroup trial, Kirkwood, Lymph, Malignant melanoma, Median, Median survival, Melanoma, Melanoma patients, Melanoma relapse, Metastasis, Metastatic melanoma, Nodal, Node, Oncol, Oncology, Overall survival, Primary melanoma, Prognostic, Randomised, Randomised trials, Randomized, Randomized trials, Recombinant leukocyte, Regimen, Regional lymph node involvement, Relapse, Relapse rate, Renal cell carcinoma, Resected, Resected melanoma, Tarhini, Tarhini kirkwood interferon, Tumor cells, Ulceration, Vaccine, Wheatley, York academy.
Teeft :
- Adjuvant, Adjuvant interferon, Adjuvant therapy, Autoimmunity, Clin, Cutaneous, Cutaneous melanoma, Cytokine, Eggermont, Eortc, Individual patient data, Interferon, Intergroup trial, Kirkwood, Lymph, Malignant melanoma, Median, Median survival, Melanoma, Melanoma patients, Melanoma relapse, Metastasis, Metastatic melanoma, Nodal, Node, Oncol, Oncology, Overall survival, Primary melanoma, Prognostic, Randomised, Randomised trials, Randomized, Randomized trials, Recombinant leukocyte, Regimen, Regional lymph node involvement, Relapse, Relapse rate, Renal cell carcinoma, Resected, Resected melanoma, Tarhini, Tarhini kirkwood interferon, Tumor cells, Ulceration, Vaccine, Wheatley, York academy.

Abstract

Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable in vivo using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.

Url:

https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/pdf

DOI: 10.1111/j.1749-6632.2009.05073.x

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000E81
to stream Istex, to step Curation: 000E81
to stream Istex, to step Checkpoint: 001F36
to stream Main, to step Merge: 00AF03
to stream Main, to step Curation: 00A754

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
<author><name sortKey="Tarhini, Ahmad A" sort="Tarhini, Ahmad A" uniqKey="Tarhini A" first="Ahmad A." last="Tarhini">Ahmad A. Tarhini</name>
</author>
<author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC</idno>
<date when="2009" year="2009">2009</date>
<idno type="doi">10.1111/j.1749-6632.2009.05073.x</idno>
<idno type="url">https://api.istex.fr/document/3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000E81</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000E81</idno>
<idno type="wicri:Area/Istex/Curation">000E81</idno>
<idno type="wicri:Area/Istex/Checkpoint">001F36</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001F36</idno>
<idno type="wicri:doubleKey">0077-8923:2009:Tarhini A:clinical:and:immunologic</idno>
<idno type="wicri:Area/Main/Merge">00AF03</idno>
<idno type="wicri:Area/Main/Curation">00A754</idno>
<idno type="wicri:Area/Main/Exploration">00A754</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main">Clinical and Immunologic Basis of Interferon Therapy in Melanoma</title>
<author><name sortKey="Tarhini, Ahmad A" sort="Tarhini, Ahmad A" uniqKey="Tarhini A" first="Ahmad A." last="Tarhini">Ahmad A. Tarhini</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j" type="main">Annals of the New York Academy of Sciences</title>
<title level="j" type="alt">ANNALS OF NEW YORK ACADEMY SCIENCES</title>
<idno type="ISSN">0077-8923</idno>
<idno type="eISSN">1749-6632</idno>
<imprint><biblScope unit="vol">1182</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="47">47</biblScope>
<biblScope unit="page" to="57">57</biblScope>
<biblScope unit="page-count">11</biblScope>
<publisher>Blackwell Publishing Inc</publisher>
<pubPlace>Malden, USA</pubPlace>
<date type="published" when="2009-12">2009-12</date>
</imprint>
<idno type="ISSN">0077-8923</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0077-8923</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant</term>
<term>Adjuvant interferon</term>
<term>Adjuvant therapy</term>
<term>Autoimmunity</term>
<term>Clin</term>
<term>Cutaneous</term>
<term>Cutaneous melanoma</term>
<term>Cytokine</term>
<term>Eggermont</term>
<term>Eortc</term>
<term>Individual patient data</term>
<term>Interferon</term>
<term>Intergroup trial</term>
<term>Kirkwood</term>
<term>Lymph</term>
<term>Malignant melanoma</term>
<term>Median</term>
<term>Median survival</term>
<term>Melanoma</term>
<term>Melanoma patients</term>
<term>Melanoma relapse</term>
<term>Metastasis</term>
<term>Metastatic melanoma</term>
<term>Nodal</term>
<term>Node</term>
<term>Oncol</term>
<term>Oncology</term>
<term>Overall survival</term>
<term>Primary melanoma</term>
<term>Prognostic</term>
<term>Randomised</term>
<term>Randomised trials</term>
<term>Randomized</term>
<term>Randomized trials</term>
<term>Recombinant leukocyte</term>
<term>Regimen</term>
<term>Regional lymph node involvement</term>
<term>Relapse</term>
<term>Relapse rate</term>
<term>Renal cell carcinoma</term>
<term>Resected</term>
<term>Resected melanoma</term>
<term>Tarhini</term>
<term>Tarhini kirkwood interferon</term>
<term>Tumor cells</term>
<term>Ulceration</term>
<term>Vaccine</term>
<term>Wheatley</term>
<term>York academy</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term>
<term>Adjuvant interferon</term>
<term>Adjuvant therapy</term>
<term>Autoimmunity</term>
<term>Clin</term>
<term>Cutaneous</term>
<term>Cutaneous melanoma</term>
<term>Cytokine</term>
<term>Eggermont</term>
<term>Eortc</term>
<term>Individual patient data</term>
<term>Interferon</term>
<term>Intergroup trial</term>
<term>Kirkwood</term>
<term>Lymph</term>
<term>Malignant melanoma</term>
<term>Median</term>
<term>Median survival</term>
<term>Melanoma</term>
<term>Melanoma patients</term>
<term>Melanoma relapse</term>
<term>Metastasis</term>
<term>Metastatic melanoma</term>
<term>Nodal</term>
<term>Node</term>
<term>Oncol</term>
<term>Oncology</term>
<term>Overall survival</term>
<term>Primary melanoma</term>
<term>Prognostic</term>
<term>Randomised</term>
<term>Randomised trials</term>
<term>Randomized</term>
<term>Randomized trials</term>
<term>Recombinant leukocyte</term>
<term>Regimen</term>
<term>Regional lymph node involvement</term>
<term>Relapse</term>
<term>Relapse rate</term>
<term>Renal cell carcinoma</term>
<term>Resected</term>
<term>Resected melanoma</term>
<term>Tarhini</term>
<term>Tarhini kirkwood interferon</term>
<term>Tumor cells</term>
<term>Ulceration</term>
<term>Vaccine</term>
<term>Wheatley</term>
<term>York academy</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adjuvant</term>
<term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Interferon α2b (IFN‐α2b) at high dosage is critical to the reversal of signaling defects in T cells of melanoma patients, and to the durable effector (α DC1) polarization of dendritic cells. These immunoregulatory effects appear to be uniquely achieved with levels of IFN‐α only attainable in vivo using the high‐dose regimen of IFN‐α2b (HDI). Three US cooperative group studies have evaluated the benefit of HDI as an adjuvant therapy for high‐risk melanoma. All have demonstrated significant and durable reduction in the frequency of relapse, while the first and third trials have demonstrated significant improvements in the fractions of patients surviving compared with observation (E1684) or with a ganglioside vaccine (GMK, E1694). A meta‐analysis of 13 randomized trials evaluating adjuvant IFN therapy has now also demonstrated significant benefits for IFN in terms of RFS and OS. Research of IFN‐α in melanoma is now focused on identifying prognostic markers of outcome and predictors of therapeutic response.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Tarhini, Ahmad A" sort="Tarhini, Ahmad A" uniqKey="Tarhini A" first="Ahmad A." last="Tarhini">Ahmad A. Tarhini</name>
</region>
<name sortKey="Kirkwood, John M" sort="Kirkwood, John M" uniqKey="Kirkwood J" first="John M." last="Kirkwood">John M. Kirkwood</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A754 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A754 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:3DE5CD287919AFCF56FEE0BB6447281F88DBEFFC
   |texte=   Clinical and Immunologic Basis of Interferon Therapy in Melanoma
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Clinical and Immunologic Basis of Interferon Therapy in Melanoma

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri